Rapid application of infliximab. Efficacy and complications;Infliximab en infusión intravenosa rápida. Eficacia y complicaciones

Reumatologia Clinica

Volumn 3, Issue 4, 2007, Pages 171-175

  Bañuelos Ramírez, David ^a,c   Ramírez Palma, María Magdalena ^b   Balcázar Sánchez, María Elena ^a   Sánchez Alonso, Silvia ^a  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c NONE   (Mexico)

Author keywords

Efficacy; Infliximab; Rapid infusion; Safety

Indexed keywords

INFLIXIMAB;

ANKYLOSING SPONDYLITIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG SAFETY; ERYTHEMA; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; VISUAL ANALOG SCALE;

EID: 34548805947     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/S1699-258X(07)73616-1     Document Type: Article

References (22)

1. Generini S, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G, et al. Infliximab in spondyloarthrpathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis. 2004;63:1664-9.
2. Demetter P, De Vos M, Van Huysse JA, Baeten D, Ferdinande L, Peeters H, et al. Colon mucosa of patients both with spondyloarthritis and Crohn's disease is enriched with macrophages expressing the scavenger receptor CD163. Ann Rheum Dis. 2005;64:321-4.
3. Bell S, Kamm MA. Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease. Lancet. 2000;355:858-60.
4. Van den Bosch F, Kruithof E, Baeten D, Herssens A, De Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum. 2002;46:755-65.
5. Yazdani-Biuki B, Stadlmaier E, Mulabecirovic A, Brezinschek R, Tilz G, Demel U, et al. Blockade of tumour necrosis factor α significantly alters the serum level of IgG and IgA rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64:1224-6.
6. Barrera P, Joosten LA, Den Broeder AA, Van de Putte LB, Van Riel PL, Van den Berg WB. Effects of treatment with a fully human anti-tumour necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFα in patients with rheumatoid arthritis. Ann Rheum Dis. 2001;60:660-9.
7. Kruithof E, Baeten D, Van den Bosch F, Mielants H, Veys EM, De Keyser F. Histological evidence that infliximab tratments leads to downregulation of inflammation and tissue remodelling of the synovial membrana in spondylorthropathy. Ann Rheum Dis. 2005;64:529-36.
8. Van Oosterhout M, Levarht EWN, Sant JK, Huizinga TWJ, Toes REM, Van Laar JM. Clinical efficacy of infliximab plus mehotrexate in DMARD naïve and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNFα and IL18 but not CXCL12. Ann Rheum Dis. 2005;64:537-43.
9. Keller C, Webb A, Davis J. Cytokines in the seronegative spondylorthropathies and their modification by TNF blockade: a brief report and literature review. Ann Rheum Dis. 2003;62:1128-32.
10. Temekonidis TI, Alamanos Y, Nikas SN, Bougias DV, Georgiadis AN, Volugari PV, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis. 2003;62:1218-20.
11. Familian A, Voskuyl AE, Van Mierlo GJ, Heijst HA, Twisk JW, Dijkamns BA, et al. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64:1003-8.
12. Akinson JP. C-reactive protein: a rheumatologist's friends revisited. Arthritis Rheum. 2001;44:995-6.
13. Kruithof E, Baeten D, Van den Bosch F, Mielants H, Veys EM, De Keyser F. Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodeling of the synovial membrane in spondyloarthrpathy. Ann Rheum Dis. 2005;64:529-36.
14. Elliot MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36:1681-90.
15. Maini R, St Clair EW, Breedved F, Furst D, Kolden J, Weissman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932-9.
16. Fitzcharles MA, Clayton CS, Menard HA. The use of infliximab in academic rheumatology practice: an audit of early clinical experience. J Rheumatol. 2002;29:2525-30.
17. Neven N, Vis M, Voskuyl AE, Wolbink GJ, Nurmohamed MT, Dijkmans BAC, et al. Adverse events in patients with rheumatoid arthritis treated with infliximab in daily clinical practice. Ann Rheum Dis. 2005; 64:645-6.
18. Nikas SN, Temekonidis TI, Zikou AK, Argyropoulou MI, Efremidis S, Drosos AA. Treatment of resistant rheumatoid arthritis by intra-articular infliximab injections: a pilot study. Ann Rheum Dis. 2004;63:102-3.
19. Van Vollenhoven, Gullström, Klareskog L. Feasibility of 1 hour infliximab infusions [carta]. Ann Rheum Dis. 2005;64:654.
20. Bañuelos-Ramírez D, Rojas-Rodríguez J, Holguín-Dorador IG. Anticuerpos monoclonales anti-TNF, más metotrexato en artritis reumatoide resistente. Rev Mex Reumat. 2003;18:281-6.
21. Balcázar-Sánchez ME, Bañuelos-Ramírez D, Salinas-Saldivar S, Sánchez-Alonso S. Estudio comparativo de aplicación de infliximab en 2 horas vs 1/2 hora a 45 minutos. Rev Mex Reumat. 2005;20:69.
22. Van Eijk Y, Boonen A, Schulpen G, Schrijnemaekers V, Fiolet H, Van del Linden Sj. Safety and patient satisfaction of infliximab administration in an extramural setting supervised by a rheumatology specialist nurse. Ann Rheum Dis. 2006;65:276.